Save up -80% on Febuxostat
Note: this is a drug discount program, not an insurance plan.
Pharmacists and Patients support.
2018 Price of Febuxostat
* price without discount in nearest pharmacy. Price may vary.
Claim your free Febuxostat discount card
We offer free Febuxostat coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Febuxostat every time. What are you waiting for? Claim your prescription drug card now!
Febuxostat volume of distribution
The mean apparent steady state volume of distribution (Vss/F) of febuxostat was approximately 50 L (CV ~40%)
About RX24Drugs
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Febuxostat
Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management. Febuxostat is not recommended for the treatment of asymptomatic hyperuricemia. Febuxostat is marketed under the trade name Uloric by Takeda Pharmaceuticals America, Inc., and was approved by the FDA in February 2009.
Febuxostat mechanism of action
Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations.
Dosage forms of Febuxostat
| Form | Route | Strength |
|---|---|---|
| Film-coated tablet | Oral use | 120 mg |
| Film-coated tablet | Oral use | 80 mg |
| Tablet, film coated | oral | 40 mg/1 |
Prescription Generics
true
International Brands
Febuxostat
Synonyms
2-(3-cyano-4-isobutoxyphenyl)-4-methyl- 1,3-thiazole-5-carboxylic acid Febuxostat
Manufacturers
Ranbaxy Pharmaceuticals Inc.
CAS number
144060-53-7
UNII
101V0R1N2E
State
solid
Affected organisms
Humans and other mammals
Indication of Febuxostat
For the treatment of hyperuricemia in patients with gout.
Toxicity of Febuxostat
The FDA adverse event reporting system database, AERS, indicated potential signals of febuxostat-associated cardiovascular thromboembolic events. AERS is not capable of establishing the causal link and detecting the true frequency of an adverse event associated with a drug. The positive IC value found in this study merits continued surveillance and assessment of cardiovascular thromboembolic events associated with Febuxostat.
RX24 Drugs Disclaimer: before buying a Febuxostat on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.
